Association of prostate‐specific antigen density with prostate cancer mortality after a benign systematic prostate biopsy result
BJU International · 2025-05 · 135 (5) · 841-850
DOI: 10.1111/bju.16641 ↗Kurz gefasst
Fachartikel in der Zeitschrift BJU International, online erschienen am 22.01.2025. Verfasst von Juho Pylväläinen und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Radiology, HUS Diagnostic Centre, Helsinki University Hospital, Helsinki, Finland. Hauptthemen laut MEDLINE: Prostatic Neoplasms, Prostate-Specific Antigen, Prostate. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 31 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Syöpäsäätiö, Helsinki University Hospital, Jane ja Aatos Erkon Säätiö.
Abstract (Originalsprache)
Objective
To assess the association between prostate‐specific antigen (PSA) density (PSAD) and prostate cancer mortality after a benign result on systematic transrectal ultrasonography (TRUS)‐guided prostate biopsy. Patients and Methods This retrospective study used data from the Finnish Randomised Study of Screening for Prostate Cancer (FinRSPC) collected between 1996 and 2020. We identified men aged 55–71 years randomised to the screening arm with PSA ≥4.0 ng/mL and a benign systematic TRUS‐guided biopsy result. The cumulative prostate cancer mortality of men stratified by a PSAD cutoff of 0.15 ng/mL/cm 3 was modelled with competing risk functions. The ability of PSAD, PSA, and base variables (age at biopsy, DRE result, socioeconomic status, 5α‐reductase inhibitor usage, family history, and Charlson Comorbidity Index (CCI)) to predict prostate cancer death was compared using c ‐statistics and a likelihood ratio test.
Results
After excluding 10 men without PSA data within 2 years of the biopsy and 65 without prostate volume data, 2276 men were eligible for inclusion in the study. A total of 50 men died from prostate cancer and 1028 from other causes during a median (interquartile range) follow‐up of 17.4 (13.2–20.9) years. The cumulative prostate cancer mortality of men with PSAD
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Radiology, HUS Diagnostic Centre, Helsinki University Hospital, Helsinki, Finland.
- Research Program in Systems Oncology, Faculty of Medicine, University of Helsinki, Helsinki, Finland.
- Cancer Society of Finland, Helsinki, Finland.
- Faculty of Social Sciences (Health Sciences), Prostate Cancer Research Center, Tampere University, Tampere, Finland.
- UKK Institute for Health Promotion Research, Tampere, Finland.
- Department of Urology, Helsinki University Hospital, Helsinki, Finland.
ORCID-Profile: Juho Pylväläinen, Kirsi Talala, Jani Raitanen, Antti Rannikko, Anssi Auvinen
Förderung
- Syöpäsäätiö
- Helsinki University Hospital
- Jane ja Aatos Erkon Säätiö
Zitieren
APA
Pylväläinen, J., Talala, K., Raitanen, J., Rannikko, A., & Auvinen, A. (2025). Association of prostate‐specific antigen density with prostate cancer mortality after a benign systematic prostate biopsy result. BJU International, 135(5), 841-850. https://doi.org/10.1111/bju.16641
Vancouver
Pylväläinen J, Talala K, Raitanen J, Rannikko A, Auvinen A. Association of prostate‐specific antigen density with prostate cancer mortality after a benign systematic prostate biopsy result. BJU International. 2025;135(5):841-850. doi:10.1111/bju.16641
BibTeX
@article{Pylvlinen2025,
author = {Pylväläinen, Juho and Talala, Kirsi and Raitanen, Jani and Rannikko, Antti and Auvinen, Anssi},
title = {Association of prostate‐specific antigen density with prostate cancer mortality after a benign systematic prostate biopsy result},
journal = {BJU International},
year = {2025},
volume = {135},
number = {5},
pages = {841--850},
doi = {10.1111/bju.16641}
}
EUVIMED